DOCSLIB.ORG

Drug-Facilitated Sexual Assault in the U.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants. Subjects provided two urine specimens, a hair specimen and completed a questionnaire describing the assault, as well as any drugs they were using. The three specimens were then analyzed to evaluate the self-reporting of illegal drugs and the number of drugs found in the subjects. Following this analysis, the results were combined with the subject’s account of the assault and evaluated as to whether DFSA was a possibility. A total of 144 subjects were enrolled and the drugs analyzed for were found in 61.8% of the subjects with 4.9% positive for the classic “date-rape” drugs. For the evaluation of the validity of self-reporting of drug use, three drugs were employed; marijuana, cocaine, and amphetamines. We hypothesized that sexual assault complainants would be more truthful in their reporting than other populations studied. However, in this study, subjects’ positive for these drugs reported their usage approximately 40% of the time. DFSA was evaluated for each subject based on criteria developed for this work. In this study, 4.2% of the subjects were evaluated as to have been victims of DFSA through surreptitious drugging. When voluntary drug use by the subject is included, 35.4% of our subjects were estimated to have been victims of DFSA. The true value of DFSA for our subjects 2 is most likely to be between these two estimates. This work is the first to include toxicological analyses with the subject’s statements to determine DFSA. 3 LIST OF ABBREVIATIONS AMPS - Amphetamines BZ - Benzodiazepines BSTFA - Bis(trimethylsilyl)trifluoroacetamide CNS - Central Nervous System DEA - Drug Enforcement Agency DFSA - Drug Facilitated Sexual Assault DOA - Drug of Abuse FBI - Federal Bureau of Investigation GABA - Gamma Aminobutyric Acid GC/MS- Gas Chromatography / Mass Spectrometry GHB - Gamma-hydroxybutyrate IRB - Institutional Review Board LOD - Limit of Detection MBHFBA- N-Methyl-bis(heptafluorobutyramide) MDMA- Methylenedioxy-n-methylamphetamine MG - Milligram ML - Milliliter MTBSTFA- N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide MTF - Monitoring the Future NAD - Nicotinamide Adenine Dinucleotide NCVS - National Crime Victimization Survey NFLIS - National Forensic Laboratory Information System 4 NG - Nanogram NIDA - National Institute of Drug Abuse NIJ - National Institute of Justice OTC - Over the Counter PCP - Phencyclidine RAINN - Rape, Abuse, & Incest National Network (www.rainn.org) SAMHSA- Substance Abuse and Mental Health Services Administration SIM - Selected Ion Monitoring SOFT - Society of Forensic Toxicologists SOP - Standard Operating Procedure SSRI - Selective Serotonin Reuptake Inhibitor TCA - Tricyclic Antidepressant THC - Tetrahydrocannabinol (marijuana) TMCS - Trimethylchlorosilane UCR - Uniform Crime Reports UCT - United Chemical Technologies USDTL- United States Drug Testing Laboratories 5 SUMMARY Sexual assault is a serious problem that is estimated to affect 64 per 100,000 females each year. The use of drugs in sexual assault has recently been reported in journals and through the media. Individuals who use drugs, with or without alcohol, are thought to be at a significantly higher risk for sexual assault. In some cases, the substances are taken voluntarily by the victims, impairing their ability to make decisions. In other cases the substances are given to the victims surreptitiously which may decrease their ability to identify a dangerous situation or to resist the perpetrator. The term drug-facilitated sexual assault (DFSA) has been coined to describe this subset of sexual assault. However, it is not precisely known how often drugs are used to facilitate sexual assault. Some of the drugs that could be used in DFSA cause unconsciousness, impair the victim’s memory, or limit their decision-making ability. There has been one previous study that attempted to determine the prevalence of drugs in sexual assault complainants. However, the study only accepted subjects with a drug history or those who believed that they were given a drug surreptitiously. Analytically, the study did not include many prescription and over-the-counter drugs that could be used in DFSA. The study also did not attempt to determine if the subjects were victims of DFSA, only to describe the drugs in their system when they presented to the clinic. This study was developed to correct the problems in the previous study by accepting subjects without any bias. Urine and hair specimens were then analyzed for approximately 45 drugs that have either been detected in sexual assault victims, or whose pharmacology could be exploited for DFSA. Each case was then analyzed based on the subject’s description of the assault, the drugs they admitted to using, and the toxicology analysis. For this work, two definitions of DFSA were used; one only included presumed surreptitious drugging, while the 6 second included subject’s whose intended drug use may have led to the assault. The estimated prevalence of DFSA was then assessed. An IRB-approved, multi-jurisdictional study was conducted that included four regionally diverse clinics. The clinics were located in Texas, California, Minnesota, and Washington State. Each clinic was provided with sexual assault kits and asked to enroll willing sexual assault complainants. When a subject was enrolled, a urine specimen was initially provided. One week later, the subject was asked to provide an additional urine specimen as well as a hair specimen. The subject then completed a questionnaire describing the details about the alleged assault, as well as any illegal, prescription or OTC drugs they were using. The three specimens were then analyzed to evaluate the validity of self-reporting of sexual assault complainants, the number of drugs found in the subjects, and whether drugs that could be used in DFSA were found. Following this analysis, the results were combined with the subject’s account of the assault and evaluated as to whether DFSA was a possibility. A total of 144 subjects were enrolled from all four participating clinics with only two clinics supplying the desired amount of 35 subjects. The racial profile of the enrolled subjects correlates well with the census data for the U.S. The ages of the subjects ranged from 18 to 56 years of age, with a mean of 26.6 years, which corresponded well with previous studies on sexual assault complainants. Only 41% of the enrolled subjects returned for the second visit, which was considerably lower than desired. The analyzed drugs were found in 61.8% of the subjects with 4.9% positive for the classic “date-rape” drugs. For the evaluation of the validity of self-reporting of drug use, three drugs were employed; marijuana, cocaine, and amphetamines. These were chosen as they would 7 not normally be given surreptitiously, thus the subject had to willingly take the drug. Also, these drugs are illegal and may affect the subject’s truthfulness. Previous studies on self-reporting of illegal drug usage have shown that different subsets of the population are more truthful than others. However, no studies have been done on sexual assault complainants. We hypothesized that sexual assault complainants would be more truthful in their reporting than other populations studied. However, in this study, subjects reported their usage of the above three drugs approximately 40% of the time. The number of drugs found in the subjects was compared to previous work on drug use among the general population as well as the drugs found in the previously mentioned DFSA study. This study had nearly 62% of the patients’ positive for one of the drugs being analyzed, which correlates extremely well with the previous DFSA study. When compared to a national survey on drug use, MTF, our subject’s reported drug use compared well with the reported drug use by the general population. However, as seen above, our subjects underreported their drug usage and when the actual number of positives is compared to MTF; our subjects had a much higher rate of drug use. DFSA was evaluated for each subject based on specific criteria we developed. DFSA1 is the conservative estimate of DFSA which only accepts surreptitious drug use as the indicator for DFSA. In this study, 4.2% of the subjects were evaluated as to have been victims of DFSA by this method. DFSA2 includes the criteria for DFSA1; however, it also includes voluntary drug use by the subject which may have facilitated the sexual assault (i.e., the assault might not have happened if the subject had not used the drug).
Recommended publications
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution

    Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution

    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
  • Drug & Alcohol Testing Program

    Drug & Alcohol Testing Program

    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts

    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
  • Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity

    Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity

    molecules Review Metabolic-Hydroxy and Carboxy Functionalization of Alkyl Moieties in Drug Molecules: Prediction of Structure Influence and Pharmacologic Activity Babiker M. El-Haj 1,* and Samrein B.M. Ahmed 2 1 Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, Fufairah 00971, UAE 2 College of Medicine, Sharjah Institute for Medical Research, University of Sharjah, Sharjah 00971, UAE; [email protected] * Correspondence: [email protected] Received: 6 February 2020; Accepted: 7 April 2020; Published: 22 April 2020 Abstract: Alkyl moieties—open chain or cyclic, linear, or branched—are common in drug molecules. The hydrophobicity of alkyl moieties in drug molecules is modified by metabolic hydroxy functionalization via free-radical intermediates to give primary, secondary, or tertiary alcohols depending on the class of the substrate carbon. The hydroxymethyl groups resulting from the functionalization of methyl groups are mostly oxidized further to carboxyl groups to give carboxy metabolites. As observed from the surveyed cases in this review, hydroxy functionalization leads to loss, attenuation, or retention of pharmacologic activity with respect to the parent drug. On the other hand, carboxy functionalization leads to a loss of activity with the exception of only a few cases in which activity is retained. The exceptions are those groups in which the carboxy functionalization occurs at a position distant from a well-defined primary pharmacophore. Some hydroxy metabolites, which are equiactive with their parent drugs, have been developed into ester prodrugs while carboxy metabolites, which are equiactive to their parent drugs, have been developed into drugs as per se.
  • Analgesia and Sedation in Hospitalized Children

    Analgesia and Sedation in Hospitalized Children

    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
  • Medical Review Officer Manual

    Medical Review Officer Manual

    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
  • Chapter 3 Drug/Alcohol Facilitated Sexual Assault

    Chapter 3 Drug/Alcohol Facilitated Sexual Assault

    Chapter 3 Drug/Alcohol Facilitated Sexual Assault “No drug, not even alcohol, causes the fundamental ills of society. If we’re looking for the source of our troubles, we shouldn’t test people for drugs, we should test them for stupidity, ignorance, greed and love of power.” ~ P.J. O’Rourke (1947- ) American humorist & journalist OBJECTIVES FOR THIS CHAPTER . Increase awareness and knowledge about alcohol, drugs and sexual assault . Understand the link between alcohol and sexual assault . Know the appropriate actions to take if a drugging is suspected ALCOHOL, DRUGS AND SEXUAL ASSAULT: AN INTRODUCTION1, 2 “I woke up and I wasn’t in my bed. I had no idea how I had got there, or if I have been with someone. I wondered what had happened to me, and I wondered why I couldn’t remember…” Alcohol and drugs are often weapons used by perpetrators to facilitate sexual assault. With all the news about predatory drugs, we sometimes forget that alcohol is the most common drug associated with sexual assault. Since alcohol is cheap, readily and legally available, and common among adolescents and young adults, it is important to understand the connection between alcohol and sexual assault. Note: Alcohol does not cause sexual violence nor does it give an offender an excuse to commit a sex crime. 1 Quinn, Kathleen M. “Drugs and Sexual Assault: A Dangerous Mix.” Illinois Coalition Against Sexual Assault Fall 2002 Coalition Commentary (Fall 2002.) Web. 23 September 2010. 2Predatory Drugs: Don’t Let Your Guard Down. Saint Louis Park, MN: Bacchus & Gamma. 2002. Print.
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • A Date Rape Drug

    A Date Rape Drug

    MOJ Toxicology Short Communication Open Access A contemporary facet on rohypnol: a date rape drug Abstract Volume 4 Issue 1 - 2018 Rohypnol is the common name for a drug called Flunitrazepam, the slang term used Priyanshu Jain, Navjot Kaur Kanwal is roofies. Rohypnol is believed to be most commonly used drug in commission of drug Department of Criminology and Forensic Science, Dr. H.S Gour assisted Sexual assaults in the United States, the United Kingdom, and throughout Europe, Central University, India Asia and South America and very popular in clubs and rave parties. This drug being colourless, odourless and flavourless is simply slipped in a drink, or mixed in any food Correspondence: Navjot Kaur Kanwal, Department of supplement without being suspected and is used to robe, rape or harm people therefore Criminology and Forensic Science Dr. H.S Gour Central infamously called as Date rape drugs. It is a strong hypnotic, a sedative ; an anticonvulsant; University, Sagar, India, Email [email protected] an anxiolytic ; an amnestic ; and skeletal muscle relaxant. Present paper concisely states about the effects of such drugs, scenarios, attempts to explore various analytical methods Received: December 04, 2017 | Published: January 08, 2018 available & challenges regarding its analysis posed before the toxicologist and law enforcing authorities. This communication has been sourced from scientific literature available in electronic databases and traditional literature available. Keywords: rohypnol, hypnotic, sedative, central nervous system, toxicologist Introduction One of the infamous drug among Date rape drugs, a Benzodiazepine which is a central nervous system depressant. Roche (a healthcare and Date Rape drugs usually applies to the drugs that renders us pharmaceutical company) started selling flunitrazepam (Rohypnol) in incapable of saying no, it causes sedation, impaired motor skills, 1975.
  • Updatirg the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

    Updatirg the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

    Updatirg the BeersCriteria for Potentially InappropriateMedication Use in Older Adults Resultsof a US ConsensusPanel of Experts DonnaM.Fich,PhD,RN;lamesW.Cooper,PhD,RPh;WilliamE.Wade,PhannD,FASHP,FCCP; JenniJerL. Waller, PhD;J, RossMaclean, MD; Marh H. Beers,MD Bcckground: Medication toxic effectsand drug- Reruhr: This study identified 48 individual medica- relatedproblems can have profound medical and safety tions or classeso[ medicationsto avoid in older adults consequencesfor older adults and economically affect the and their potential concernsand 20 diseases/conditions health caresystem. The purpose of this initiative was to and medicationsto be avoidedin older adultswith these reviseand update the Beerscriteria for potentially inap- conditions.Of thesepotentially inappropriate drugs, 66 propriate medicationuse in adults 65 yearsand older in wereconsidered by the panelto haveadverse outcomes the United States. of high severity. lYlcthcdr: This study used a modified Delphi method, a Concludonr: This study is an importantupdate of pre- setof proceduresand methodsfor formulating a groupjudg- viously establishedcriteria that have been widely used ment for a subject matter in which precise information is and cited. The application of the Beerscriteria and other Iacking. The criteria reviewed covered 2 types of state- tools for identifying potentially inapproprlate medica- ments: (l) medicationsor medicationclasses that should tion use will continue to enableproviders to plan inter- grnerally be avoidedin persons 65 years or older because
  • Misperceptions About Contraceptives Persist

    Misperceptions About Contraceptives Persist

    30 Women’s Health FAMILY P RACTICE N EWS • September 1, 2008 Misperceptions About Contraceptives Persist BY DOUG BRUNK trauterine device use; 50% thought IUD (SOGC). There may be inadequate in- Oral contraceptives are also safe in women San Diego Bureau failure was a major risk; and fewer than struction with regard to contraception in older than age 35 if they are healthy non- one-third would recommend an IUD as an physician-training programs, she said. smokers, and in women with systemic lu- C ALGARY, ALTA. — Physicians may option for nulliparous women, for post- “Not everybody does IUD insertions, sub- pus erythematosus provided they have no have a surprising number of misconcep- coital contraception, for women with fi- dermal progestin implant, or vasectomy.” antiphospholipid antibodies, vascular dis- tions about birth control, according to re- broids, or for women who had pelvic in- Other barriers to effective contraceptive ease, or nephritis. cent responses to a survey by 96 family flammatory disease within the last year use include exaggerated concerns about Another common exaggerated concern physicians in Kingston, Ont. (Can. Fam. Physician 2008;54:560-6). potential side effects. For example, women is that the use of oral and transdermal Contrary to evidence in the medical lit- “Only 41% of these physicians inserted with diabetes may use oral contraceptives patch contraceptives cause weight gain. erature, more than 60% of respondents IUDs,” Dr. Amanda Black said at the an- if they have no end-organ damage, said Dr. However, a recent Cochrane systematic re- thought pelvic inflammatory disease and nual meeting of the Society of Obstetri- Black of the division of general obstetrics view of randomized, controlled data con- ectopic pregnancy were major risks of in- cians and Gynaecologists of Canada and gynecology at the Ottawa Hospital.